Skip to main content
. 2020 Dec 29;104:433–440. doi: 10.1016/j.ijid.2020.12.073

Figure 2.

Figure 2

(a) Changes over time in immune response-related markers: comparison between Cohort 1 and Cohort 2 (T0: basal; T1 after first administration of canakinumab; T2 after 7–10 days from the second administration of canakinumab). The N/L ratio is also reported. (b) Changes over time in immune-inflammatory-related biomarkers: comparison between Cohort 1 and Cohort 2.